Nxera Pharma to Book $10mn Milestone After Neurocrine Clears FDA Hurdle on Alzheimer's Drug
FDA acceptance of a Phase 2 filing for an Alzheimer's cognition drug licensed from Nxera Pharma triggers a $10mn payment, about ¥1.59bn, that the company will book as third-quarter revenue under a fiscal year that already assumed it.